Cambridge Cognition is pleased to announce the acquisition of Winterlight, a leader in monitoring cognitive impairment through free-speech analysis.
Read
Winterlight Labs and Genentech have announced new data showing the sensitivity of speech-based digital measures in detecting disease-related longitudinal change in Alzheimer’s disease.
Read
Winterlight is partnering with Alzheimer Center Amsterdam on a funded study to characterize speech patterns in preclinical Alzheimer's disease and develop tools for remote assessment.
Read
In collaboration with Genentech, the research team at Winterlight Labs presented new research at ADPD 2022 showing associations between speech characteristics and cerebral tau accumulation measured by tau PET imaging.
Read
We have developed an in-house pipeline that measures the performance of our NLP and machine learning tools that extract linguistic elements of speech. This allows us to continuously measure accuracy and ensure we deliver the highest quality results to our customers.
Read
Winterlight announces the launch of linguistic analysis support for French, Spanish and German.
Read
Winterlight Labs is excited to announce new academic collaborations to study speech in relation to cognitive and mental health.
Read
Original research published in Frontiers Digital Health describes how Winterlight's technology can be used to detect speech changes relating to cognitive impairment.
Read
Winterlight published a new review paper in Frontiers in Psychiatry focussing on how natural language processing has been used to study depression in older adults.
Read
At the Alzheimer's Association International Conference, Winterlight Labs presented new research on how speech characteristics are associated with Alzheimer's Disease, in collaboration with Genentech.
Read
New research published in Alzheimer's Research & Therapy examines how automatically computed speech measures correlate with clinical assessments of speech in Alzheimer's Disease and Mild Cognitive Impairment.
Read
Winterlight Labs participates in the Digital Medicine Society's Tour of Duty to develop resources for the adoption of digital measures in clinical research.
Read
Winterlight presented a poster at the SOBP annual conference exploring the use of remote speech assessments to detect signs of anxiety.
Read
Winterlight labs presented two research posters at the International Society for CNS Clinical Trials and Methodology (ISCTM) virtual annual meeting highlighting validation studies of their automated speech assessment technology.
Read
Winterlight Labs presented two research posters at the 2020 Clinical Trials on Alzheimer's Disease (CTAD) virtual meeting, highlighting new work on longitudinal speech and language changes in Frontotemporal Dementia and Alzheimer's Disease.
Read
Winterlight Labs published a paper on evaluation and validation of speech-based digital biomarkers in the journal Digital Biomarkers.
Read
Winterlight Labs presented research on crowdsourced speech data collection for developing speech biomarkers for depression at the International Society for CNS Clinical Trials and Methodology (ISCTM) virtual autumn conference.
Read
Winterlight Labs presented three research posters at the 2020 virtual edition of the Alzheimer's Association International Conference (AAIC), highlighting recent validation of speech-based biomarkers for Alzheimer's disease.
Read
Vivoryon Therapeutics will use the Winterlight speech assessment in upcoming Phase 2b clinical trial of PQ912 in Alzheimer’s Disease.
Read
The paper was accepted to "Detecting Cognitive Impairments by Agreeing on Interpretations of Linguistic Features" to NAACL. NAACL is a top-tier conference in computational linguistics and artificial intelligence that will be hosted in Minneapolis, USA in early June.
Read
Winterlight presented new research from a longitudinal study of Alzheimer’s Disease (AD) and Mild Cognitive Impairment (MCI) today at the 16th Annual Meeting of the International Society for CNS Clinical Trials and Methodology.
Read
Winterlight Labs has entered into an agreement with Pear Therapeutics to develop speech-based biomarkers to improve the efficacy of prescription digital therapeutics.
Read
Today at the Clinical Trials for Alzheimer’s Disease (CTAD) Conference, Winterlight presented preliminary data on a speech-based language composite score for Frontotemporal Dementia and improved tracking of cognitive decline in Healthy Seniors.
Read
Hikma Pharmaceuticals PLC announces that its venture capital arm, Hikma Ventures has led a CAD 5.6 million oversubscribed round of financing for Winterlight Labs Inc. with participation from First Star Ventures, Pacific Health Ventures, existing investor Grey Sky Venture Partners and other investors.
Read
The Wall Street Journal published an article titled "What Your Voice Reveals About You" about the ability of the voice-based AI to identify individuals in the realm of fraud prevention and medicine. Winterlight Labs was featured as an example of speech being used to detect dementia such as Alzheimer’s.
Read
Winterlight announced today it is developing vocal biomarkers for monitoring disease progression in frontotemporal dementia (FTD) patients in collaboration with Alector, a biotechnology company developing therapeutics for neurodegeneration.
Read
At the 74th Annual Meeting of the Society for Biological Psychiatry, Winterlight is presenting a poster highlighting the use of verbal picture descriptions to predict cognitive status. Using data from 219 individuals who described a picture in their own words, we were able to estimate an individual’s score on the Montreal Cognitive Assessment (MoCA) within 2.6 points (8.7% error).
Read
The New York Times published an article which describes how emerging AI technologies might transform patient care, by detecting diseases earlier and indicating whether drug treatments are working in real-time. Winterlight Labs and its technology are featured here to demonstrate the potential of voice analysis in detecting and treating clinical conditions.
Read
Winterlight Labs was featured on TVO's The Agenda with Steve Paikin. The episode titled "Battling Dementia with the Power of AI" showcases Winterlight Lab's partnership with Revera Living.
Read
The agreement was facilitated by Johnson & Johnson Innovation LLC. The collaboration will initially focus on developing a sensitive digital biomarker that can distinguish patients with mild cognitive impairment, an early stage of Alzheimer's Disease (AD), from healthy elderly subjects.
Read
Two of our research papers were accepted and will be presented at NeurIPS (the conference previously known as NIPS) workshops next week in Montreal. NeurIPS is the leading machine learning conference - tickets sold out in 20 minutes.
Read
No significant improvements were observed in Mini Mental State Examination (MMSE) scores or CANTAB measures of cognition between treatment (COR388) and placebo groups. In contrast, Winterlight’s cognitive assessment showed statistically significant improvements from baseline to endpoint in the treatment group, with no such differences seen in the placebo group.
Read
Winterlight Labs has closed $1,000,000 in additional seed funding from Grey Sky Venture Partners (GSVP), based on Bellevue Washington. In total, Winterlight Labs has raised $1.5 million.
Read
Winterlight will be piloting its speech-based cognitive assessment at one of Revera's senior care homes in Toronto with 50 participants over a 6 month period. This pilot was funded via the Ontario Centres of Excellence (OCE) Health Technology Fund (HTF).
Read
Liam Kaufman describes how the technology works and gives a demonstration of the app.
Read
Winterlight Labs closed the first tranche of $500,000 in seed funding from Novatio Ventures, an early stage life sciences investment firm.
Read
Winterlight Co-founder Frank Rudzicz explains how the technology works in Wired Magazine.
Read
The research will evaluate Winterlight's proprietary technology for analyzing voice samples obtained from Janssen Research & Development's ongoing clinical trials in Alzheimer's and neurodegenerative diseases.
Read
Winterlight Labs has won the AGE-WELL Pitch Competition: Technology to Support People with Dementia. Ten teams from Canada and around the world competed in the AGE-WELL Pitch Competition.
Read
Winterlight Labs has graduated from the Rotman Business School’s Creative Destruction Lab (CDL). The CDL works with startups that employ innovations in technology and business models that promise a chance of delivering massive improvements to economic productivity and human welfare.
Read
Winterlight co-founders Katie Fraser, Frank Rudzicz, and Winterlight scientific advisor Jed Meltzer have discovered how to diagnose Alzheimer's disease with more than 82 per cent accuracy by evaluating the interplay between four linguistic factors.
Read